Prognostic value of TP53 gene mutation in adjuvant treated breast cancer patients |
| |
| Authors: | B.L. Powell S. Bydder F. Grieu G. Gnanasampanthan H. Elsaleh R. Seshadri E.M.J.J. Berns B. Iacopetta |
| |
| Affiliation: | (1) Department of Surgery, University of Western Australia, Nedlands, Australia;(2) Department of Radiation Oncology, Sir Charles Gairdner Hospital, Nedlands, Australia;(3) Department of Hematology and Oncology, Flinders Medical Centre, Flinders University, Bedford Park, South Australia, Australia;(4) Department of Medical Oncology, Division of Endocrine Oncology, University Hospital Rotterdam/DDHK, Rotterdam, The Netherlands |
| |
| Abstract: | ![]()
We investigated the prognostic significance of mutation to the TP53 tumor suppressor gene in a series of 908 breast cancer patients treated with or without adjuvant therapies. The frequency of TP53 mutation detected by single strand conformation polymorphism (SSCP) was 19.4% (176/908) in the overall tumor series. In multivariate analysis, TP53 mutation was independently associated with worse survival in the overall (HR=2.1, 95% CI [1.5–3.1], P<0.0001), non-adjuvant treated (HR=2.2, 95% CI [1.2–4.2], P=0.017) and adjuvant treated (HR=2.0, 95% CI [1.3–3.1], P=0.0009) patients. |
| |
| Keywords: | adjuvant therapy breast carcinoma chemotherapy hormonal therapy prognostic marker predictive marker TP53 |
| 本文献已被 SpringerLink 等数据库收录！ |
|
